Differing sensitivity of tumor cells to apoptosis induced by iron deprivation in vitro

. 2001 Jul-Aug ; 37 (7) : 450-8.

Jazyk angličtina Země Německo Médium print

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid11573821

We studied the sensitivity of tumor cells to the induction of apoptosis by iron deprivation. Iron deprivation was achieved by the employment of a defined iron-deficient culture medium. Mouse 38C13 cells and human Raji cells die within 48 and 96 h of incubation in iron-deficient medium, respectively. On the contrary, mouse EL4 cells and human HeLa cells are completely resistant to the induction of death under the same experimental arrangement. Deoxyribonucleic acid fragmentation analysis by agarose gel electrophoresis as well as flow cytometric analysis after propidium iodide staining detected in 38C13 and Raji cells, but not in EL4 and HeLa cells, changes characteristic to apoptosis. The 38C13 cells, sensitive to iron deprivation, also displayed a similar degree of sensitivity to apoptosis induction by thiol deprivation (achieved by 2-mercaptoethanol withdrawal from the culture medium) as well as by rotenone (50 nM), hydroxyurea (50 microM), methotrexate (20 nM), and doxorubicin (100 nM). Raji cells shared with 38C13 cells a sensitivity to rotenone, methotrexate, doxorubicin, and, to a certain degree, to hydroxyurea. However, Raji cells were completely resistant to thiol deprivation. EI4 and HeLa cells, resistant to iron deprivation, also displayed a greater degree of resistance to most of the other apoptotic stimuli than did their sensitive counterparts. We conclude that some tumor cells in vitro are sensitive to apoptosis induction by iron deprivation, while other tumor cells are resistant. All the tumors found to be sensitive to iron deprivation in this study (four cell lines) are of hematopoietic origin. The mechanism of resistance to apoptosis induction by iron deprivation differs from the mechanism of resistance to thiol deprivation.

Zobrazit více v PubMed

Exp Cell Res. 1977 Feb;104(2):255-62 PubMed

Clin Cancer Res. 1996 Jun;2(6):1009-15 PubMed

Histol Histopathol. 1997 Jan;12 (1):291-6 PubMed

Exp Cell Res. 1989 Jun;182(2):358-69 PubMed

Br J Haematol. 1998 Aug;102(3):746-52 PubMed

Exp Hematol. 1995 May;23 (5):428-32 PubMed

Cancer Res. 1990 Sep 15;50(18):5727-30 PubMed

Clin Immunol Immunopathol. 1996 Aug;80(2):185-93 PubMed

Pathobiology. 1997;65(2):61-8 PubMed

Cancer Res. 1995 Sep 1;55(17):3817-24 PubMed

Hepatogastroenterology. 1995 Feb;42(1):31-6 PubMed

J Natl Cancer Inst. 1991 Nov 6;83(21):1582-4 PubMed

Pathobiology. 1995;63(2):65-70 PubMed

Anticancer Drugs. 1993 Jun;4(3):317-21 PubMed

Science. 1995 Mar 10;267(5203):1456-62 PubMed

Cancer Res. 1990 Aug 15;50(16):4929-30 PubMed

J Cell Biochem Suppl. 1996;24:276-87 PubMed

Br J Haematol. 1995 Jan;89(1):181-7 PubMed

Oncogene. 1994 Jul;9(7):1807-12 PubMed

Clin Cancer Res. 1995 Nov;1(11):1259-65 PubMed

J Natl Cancer Inst. 1989 Aug 16;81(16):1229-35 PubMed

Cancer Res. 1992 Aug 1;52(15):4144-8 PubMed

Cancer. 1991 Dec 15;68(12 ):2561-5 PubMed

FEBS Lett. 1994 Aug 15;350(1):139-42 PubMed

Biol Chem Hoppe Seyler. 1995 Oct;376(10):627-30 PubMed

Cell Prolif. 1999 Feb;32(1):63-73 PubMed

Adv Enzyme Regul. 1997;37:147-69 PubMed

Hybridoma. 1988 Jun;7(3):255-63 PubMed

Cancer Res. 1990 Oct 1;50(19):6295-301 PubMed

Nature. 1998 Nov 12;396(6707):119-22 PubMed

Cell. 1997 Feb 7;88(3):347-54 PubMed

Acta Haematol. 1996;95(1):66-9 PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...